Cargando…
Changes in bone biological markers after treatment of Iranian diabetic patients with pioglitazone: No relation to polymorphism of PPAR-γ (Pro12Ala)
BACKGROUND: Thiazolidinediones (TZDs) improves insulin sensitivity by activating the peroxisome proliferator-activated receptor γ (PPAR-g). We aimed to study any association between variation in bone biochemical markers and single nucleotide polymorphism (SNP) in PPAR-γ (Pro12Ala) and investigate if...
Autores principales: | Namvaran, Fatemeh, Rahimi-Moghaddam, Parvaneh, Azarpira, Negar, Dabbaghmanesh, Mohammad Hossien, Bakhshayeshkaram, Marzieh, Namvaran, Mohamad Mahdi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3793371/ https://www.ncbi.nlm.nih.gov/pubmed/24124423 |
Ejemplares similares
-
Genotyping of peroxisome proliferator-activated receptor gamma (PPAR-γ) polymorphism (Pro12Ala) in Iranian population
por: Namvaran, Fatemeh, et al.
Publicado: (2011) -
Changes in bone biological markers after treatment of Iranian diabetic patients with pioglitazone: No relation to polymorphism of PPAR-γ (Pro12Ala)
por: Mottaghi, Peyman
Publicado: (2013) -
PPARγ2(Pro12Ala) Polymorphism and Human Health
por: He, Weimin
Publicado: (2009) -
Association between PRO12ALA polymorphism of the PPAR-γ2 gene and type 2 diabetes mellitus in Iranian patients
por: Motavallian, Azadeh, et al.
Publicado: (2013) -
The Association of PPARγ Pro12Ala and C161T Polymorphisms
with Polycystic Ovary Syndrome and Their Influence on Lipid and
Lipoprotein Profiles
por: Rahimi, Zohreh, et al.
Publicado: (2018)